Metabolon, Inc. has announced it has raised $15 million in a series E financing.

Metabolon, headquartered in Research Triangle Park, N.C., provides metabolomics-based diagnostic tests and research services.

New investor Camden Partners, a Baltimore-based PE firm, led the round, with participation from Sumitomo Corp. along with existing investors Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners.

The funding is expected to support, among other things, Metabolon partner Bostwick Laboratories’ launch of Prostarix, a urine-based test that provides metabolic information on the likelihood that a patient with slightly elevated PSA scores has prostate cancer; the continued development of Metabolon’s Quantose IGT, a surrogate test for oral glucose tolerance; and Metabolon’s test for the recurrence of bladder cancer.